CRONOS GROUP INC (CRON) Fundamental Analysis & Valuation

NASDAQ:CRON • CA22717L1013

Current stock price

2.64 USD
-0.03 (-1.12%)
At close:
2.6403 USD
+0 (+0.01%)
After Hours:

This CRON fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. CRON Profitability Analysis

1.1 Basic Checks

  • In the past year CRON has reported negative net income.
  • In the past year CRON had a positive cash flow from operations.
  • CRON had negative earnings in 4 of the past 5 years.
  • In multiple years CRON reported negative operating cash flow during the last 5 years.
CRON Yearly Net Income VS EBIT VS OCF VS FCFCRON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

1.2 Ratios

  • CRON has a better Return On Assets (-0.79%) than 79.06% of its industry peers.
  • With an excellent Return On Equity value of -0.86%, CRON belongs to the best of the industry, outperforming 81.15% of the companies in the same industry.
Industry RankSector Rank
ROA -0.79%
ROE -0.86%
ROIC N/A
ROA(3y)-1.25%
ROA(5y)-9.2%
ROE(3y)-1.24%
ROE(5y)-9.62%
ROIC(3y)N/A
ROIC(5y)N/A
CRON Yearly ROA, ROE, ROICCRON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

1.3 Margins

  • With a decent Gross Margin value of 42.81%, CRON is doing good in the industry, outperforming 62.30% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CRON has grown nicely.
  • The Profit Margin and Operating Margin are not available for CRON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34%
GM growth 5YN/A
CRON Yearly Profit, Operating, Gross MarginsCRON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1K 2K 3K 4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. CRON Health Analysis

2.1 Basic Checks

  • CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CRON has been reduced compared to 1 year ago.
  • Compared to 5 years ago, CRON has more shares outstanding
  • CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRON Yearly Shares OutstandingCRON Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
CRON Yearly Total Debt VS Total AssetsCRON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 7.34 indicates that CRON is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 7.34, CRON is in the better half of the industry, outperforming 79.58% of the companies in the same industry.
  • There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.34
ROIC/WACCN/A
WACC8.74%
CRON Yearly LT Debt VS Equity VS FCFCRON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • CRON has a Current Ratio of 19.59. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 19.59, CRON belongs to the best of the industry, outperforming 91.62% of the companies in the same industry.
  • CRON has a Quick Ratio of 18.62. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 18.62, CRON belongs to the best of the industry, outperforming 91.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 19.59
Quick Ratio 18.62
CRON Yearly Current Assets VS Current LiabilitesCRON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CRON Growth Analysis

3.1 Past

  • CRON shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -104.00%.
  • CRON shows a strong growth in Revenue. In the last year, the Revenue has grown by 24.63%.
  • The Revenue has been growing by 25.70% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-104%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-103.64%
Revenue 1Y (TTM)24.63%
Revenue growth 3Y19.11%
Revenue growth 5Y25.7%
Sales Q2Q%46.96%

3.2 Future

  • CRON is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -72.39% yearly.
  • The Revenue is expected to grow by 0.19% on average over the next years.
EPS Next Y1757.5%
EPS Next 2Y359.62%
EPS Next 3Y210.9%
EPS Next 5Y-72.39%
Revenue Next Year31.91%
Revenue Next 2Y23.45%
Revenue Next 3Y14.53%
Revenue Next 5Y0.19%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CRON Yearly Revenue VS EstimatesCRON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M 200M
CRON Yearly EPS VS EstimatesCRON Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

2

4. CRON Valuation Analysis

4.1 Price/Earnings Ratio

  • CRON is valuated quite expensively with a Price/Forward Earnings ratio of 39.82.
  • Based on the Price/Forward Earnings ratio, CRON is valued a bit cheaper than 71.73% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of CRON to the average of the S&P500 Index (21.36), we can say CRON is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 39.82
CRON Price Earnings VS Forward Price EarningsCRON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRON Per share dataCRON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • CRON's earnings are expected to grow with 210.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y359.62%
EPS Next 3Y210.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRON Dividend Analysis

5.1 Amount

  • No dividends for CRON!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRON Fundamentals: All Metrics, Ratios and Statistics

CRONOS GROUP INC

NASDAQ:CRON (5/1/2026, 8:19:13 PM)

After market: 2.6403 +0 (+0.01%)

2.64

-0.03 (-1.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength32.28
Industry Growth47.76
Earnings (Last)02-26
Earnings (Next)05-11
Inst Owners15.11%
Inst Owner Change0.82%
Ins Owners6.61%
Ins Owner Change4.54%
Market Cap993.33M
Revenue(TTM)146.59M
Net Income(TTM)-9.45M
Analysts82.22
Price Target3.37 (27.65%)
Short Float %2.4%
Short Ratio3.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.13%
Min Revenue beat(2)-4.49%
Max Revenue beat(2)12.75%
Revenue beat(4)1
Avg Revenue beat(4)1.94%
Min Revenue beat(4)-4.49%
Max Revenue beat(4)12.75%
Revenue beat(8)4
Avg Revenue beat(8)1.09%
Revenue beat(12)5
Avg Revenue beat(12)-0.47%
Revenue beat(16)6
Avg Revenue beat(16)-2.81%
PT rev (1m)-2.18%
PT rev (3m)-8.65%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)-100%
EPS NY rev (1m)2.64%
EPS NY rev (3m)-7.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.78%
Revenue NY rev (1m)-4.4%
Revenue NY rev (3m)2.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 39.82
P/S 6.78
P/FCF N/A
P/OCF 38.4
P/B 0.91
P/tB 0.98
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)0.07
Fwd EY2.51%
FCF(TTM)0
FCFYN/A
OCF(TTM)0.07
OCFY2.6%
SpS0.39
BVpS2.91
TBVpS2.71
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -0.79%
ROE -0.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.81%
FCFM N/A
ROA(3y)-1.25%
ROA(5y)-9.2%
ROE(3y)-1.24%
ROE(5y)-9.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34%
GM growth 5YN/A
F-Score7
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 183.09%
Cap/Sales 17.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.59
Quick Ratio 18.62
Altman-Z 7.34
F-Score7
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)118.29%
Cap/Depr(5y)94.57%
Cap/Sales(3y)10.61%
Cap/Sales(5y)10.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-104%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-103.64%
EPS Next Y1757.5%
EPS Next 2Y359.62%
EPS Next 3Y210.9%
EPS Next 5Y-72.39%
Revenue 1Y (TTM)24.63%
Revenue growth 3Y19.11%
Revenue growth 5Y25.7%
Sales Q2Q%46.96%
Revenue Next Year31.91%
Revenue Next 2Y23.45%
Revenue Next 3Y14.53%
Revenue Next 5Y0.19%
EBIT growth 1Y75.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year175.59%
EBIT Next 3Y74.89%
EBIT Next 5Y-8.2%
FCF growth 1Y-103.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.27%
OCF growth 3YN/A
OCF growth 5YN/A

CRONOS GROUP INC / CRON Fundamental Analysis FAQ

What is the fundamental rating for CRON stock?

ChartMill assigns a fundamental rating of 5 / 10 to CRON.


What is the valuation status of CRONOS GROUP INC (CRON) stock?

ChartMill assigns a valuation rating of 2 / 10 to CRONOS GROUP INC (CRON). This can be considered as Overvalued.


Can you provide the profitability details for CRONOS GROUP INC?

CRONOS GROUP INC (CRON) has a profitability rating of 3 / 10.


What is the financial health of CRONOS GROUP INC (CRON) stock?

The financial health rating of CRONOS GROUP INC (CRON) is 9 / 10.